Grazia Aleppo1,2, Kimberly Webb2. 1. 1 Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 2. 2 Northwestern Medicine Diabetes Training and Education Program, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern Medical Group, Chicago, IL, USA.
Abstract
BACKGROUND: The advent of continuous glucose monitoring (CGM) technology has transformed the approach to diabetes care. Multiple CGM systems are commercially available and increased accuracy has allowed development of hybrid and automated insulin delivery systems. Evidence of CGM clinical benefits has also increased exponentially in the last decade. METHODS: Literature search, review of professional guidelines, and consensus statements were used to guide the preparation of this article. The clinical benefits of both professional and personal CGM in clinical practice as well as barriers to wider adotpion were explored. A stepped approach to review and interpretation of CGM data is suggested for use in the clinician's office regardless of the software used. RESULTS: Although increasing, the use of CGM in patients with diabetes is still not widespread; multiple barriers are still in place, despite the approval of CGM systems for patients above the age of 2 years old, the extension of coverage for Medicare beneficiaries and the integration of CGM with multiple insulin pump systems. Integration of CGM technology in clinical practice presents various challenges, from concerns relative to time constraints during office visits to lack of systematic approach to interpretation of the data. CONCLUSIONS: Understanding the usefulness of personal and professional CGM, appropriate patient selection as well as patient and provider training are crucial for the expansion of CGM therapy use in clinical practice. Utilizing the proposed stepped approach to CGM review and interpretation may allow wider adoption of CGM with more effective and efficient office visits.
BACKGROUND: The advent of continuous glucose monitoring (CGM) technology has transformed the approach to diabetes care. Multiple CGM systems are commercially available and increased accuracy has allowed development of hybrid and automated insulin delivery systems. Evidence of CGM clinical benefits has also increased exponentially in the last decade. METHODS: Literature search, review of professional guidelines, and consensus statements were used to guide the preparation of this article. The clinical benefits of both professional and personal CGM in clinical practice as well as barriers to wider adotpion were explored. A stepped approach to review and interpretation of CGM data is suggested for use in the clinician's office regardless of the software used. RESULTS: Although increasing, the use of CGM in patients with diabetes is still not widespread; multiple barriers are still in place, despite the approval of CGM systems for patients above the age of 2 years old, the extension of coverage for Medicare beneficiaries and the integration of CGM with multiple insulin pump systems. Integration of CGM technology in clinical practice presents various challenges, from concerns relative to time constraints during office visits to lack of systematic approach to interpretation of the data. CONCLUSIONS: Understanding the usefulness of personal and professional CGM, appropriate patient selection as well as patient and provider training are crucial for the expansion of CGM therapy use in clinical practice. Utilizing the proposed stepped approach to CGM review and interpretation may allow wider adoption of CGM with more effective and efficient office visits.
Authors: Roy W Beck; William V Tamborlane; Richard M Bergenstal; Kellee M Miller; Stephanie N DuBose; Callyn A Hall Journal: J Clin Endocrinol Metab Date: 2012-09-20 Impact factor: 5.958
Authors: Ana M Gómez; Guillermo E Umpierrez; Oscar M Muñoz; Felipe Herrera; Claudia Rubio; Pablo Aschner; Richard Buendia Journal: J Diabetes Sci Technol Date: 2015-08-31
Authors: Jenise C Wong; Nicole C Foster; David M Maahs; Dan Raghinaru; Richard M Bergenstal; Andrew J Ahmann; Anne L Peters; Bruce W Bode; Grazia Aleppo; Irl B Hirsch; Lora Kleis; H Peter Chase; Stephanie N DuBose; Kellee M Miller; Roy W Beck; Saleh Adi Journal: Diabetes Care Date: 2014-07-10 Impact factor: 19.112
Authors: Rodolfo J Galindo; Grazia Aleppo; David C Klonoff; Elias K Spanakis; Shivani Agarwal; Priya Vellanki; Darin E Olson; Guillermo E Umpierrez; Georgia M Davis; Francisco J Pasquel Journal: J Diabetes Sci Technol Date: 2020-06-14
Authors: Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle Journal: Endocr Rev Date: 2020-10-01 Impact factor: 19.871
Authors: John Jack L Leahy; Grazia Aleppo; Vivian A Fonseca; Satish K Garg; Irl B Hirsch; Anthony L McCall; Janet B McGill; William H Polonsky Journal: J Endocr Soc Date: 2019-10-07
Authors: Nancy Elbarbary; Othmar Moser; Saif Al Yaarubi; Hussain Alsaffar; Adnan Al Shaikh; Ramzi A Ajjan; Asma Deeb Journal: Diab Vasc Dis Res Date: 2021 Nov-Dec Impact factor: 3.291
Authors: Jason Liu; Daniel J Spakowicz; Garrett I Ash; Rebecca Hoyd; Rohan Ahluwalia; Andrew Zhang; Shaoke Lou; Donghoon Lee; Jing Zhang; Carolyn Presley; Ann Greene; Matthew Stults-Kolehmainen; Laura M Nally; Julien S Baker; Lisa M Fucito; Stuart A Weinzimer; Andrew V Papachristos; Mark Gerstein Journal: PLoS Comput Biol Date: 2021-08-23 Impact factor: 4.475